Aldeyra

ALDX | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.35

-$0.01 (-0.74%)

At close: Sep 21, 2026, 4:00 PM ET

$1.38

+$0.03 (+2.22%)

Pre-market: Sep 22, 2026, 8:03 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.74%

(1D)

Rating

Updated: Aug 25, 2026

21.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $81.43M

1D Range

1.33 1.37

52W Range

1.07 5.93

Valuation (TTM)

PE -3.46

PB 2.15

EV/EBITDA -1.71

Valuation (NTM)

Forward PE 5.18

Forward PEG 0.19

Price Target $9.67

Cash Flow

FCF Yield -11960.7%

SBC Adj. FCF Yield -12768.9%

SBC Impact -6.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 19.9% | 19.6%

FCF 3Y | 5Y -148.4% | -97.7%

Returns

ROA -48.5%

ROE -53.1%

ROIC -63.3%

Financial Health

Net Cash

$45.09M

Current Ratio 4.91

Interest Coverage -16.95

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species ...

Sector Healthcare

Industry Biotechnology

Employees 6

IPO Date May 1, 2014

Website www.aldeyra.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$10

Upside

+640.74%

Buy (1)

Hold (1)

Sell (0)

Analyst Details ➞